Jan 21, 2026 16:44 JST

Source: Eisai

Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
Highest ranked global pharmaceutical company

TOKYO, Jan 21, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been listed in the 2026 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai’s tenth inclusion on the list. Ranked 36th, Eisai is the highest ranking among global pharmaceutical companies as well as the highest ranking Japanese company listed in the Global 100 (please visit here for the Global 100 ranking).

The Global 100 evaluates the sustainability of more than 8,200 of the world’s major corporations based on the United Nation’s Sustainable Development Goals (SDGs). Since 2005, companies ranking among the top 100 in the world have been announced each year. The Global 100 companies are evaluated for sustainable revenue and its growth, and sustainable investment as defined by Corporate Knights based on publicly disclosed data from financial filings, integrated reports, or other such channels. Eisai was highly evaluated, particularly in indicators such as sustainable revenue and investment achieved through business activities, and its system reflecting sustainability targets in executive compensation.

Eisai’s corporate concept is to give first thought to patients and the people in the daily living domain, and increase the benefits that health care provides to them as well as meet their diversified healthcare needs worldwide. Based on this human health care (hhc) corporate concept, Eisai is striving to sustainably enhance corporate value by strengthening its sustainability initiatives and increasing non-financial value.

Media Inquiries:

Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
February 06 2026 10:31 JST
 
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
January 26 2026 10:37 JST
 
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
 
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
 
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
 
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
December 04 2025 17:36 JST
 
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 03 2025 17:19 JST
 
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
December 02 2025 23:01 JST
 
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
November 28 2025 22:00 JST
 
More Press release >>

Latest Press Release


More Latest Release >>